-
1.发明申请Pharmaceutical Compositions Of Cholesteryl Ester Transfer Protein Inhibitors And Hmg-Coa Reductase 有权胆固醇酯转运蛋白抑制剂和Hmg-Coa还原酶的药物组合物公开(公告)号：US20090118328A1
公开(公告)日：2009-05-07
申请号：US11920473
申请日：2006-05-22
Applicant: Dwayne Thomas Friesen , Bruno Caspar Hancock , Rodney James Ketner , David Keith Lyon , James Alan Shriver Nightingale , Ravi Mysore Shanker
Inventor： Dwayne Thomas Friesen , Bruno Caspar Hancock , Rodney James Ketner , David Keith Lyon , James Alan Shriver Nightingale , Ravi Mysore Shanker
IPC: A61K31/4706 , A61K47/38 , A61K31/41 , A61K31/40 , A61K47/32
CPC classification number: A61K45/06 , A61K9/1611 , A61K9/1635 , A61K9/1652 , A61K31/40 , A61K31/4706 , A61K2300/00
Abstract: A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-conenzyme A reductase (HMG-CoA reductase inhibitor), and a concentration enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concentration-enhancement of the CETP inhibitor when administered to an aqueous use environment.
Abstract translation: 固体无定形分散体包含胆固醇酯转移蛋白（CETP）抑制剂，3-羟基-3-甲基戊二酰辅酶A还原酶（HMG-CoA还原酶抑制剂）的抑制剂和浓度增强聚合物。 分散体中CETP抑制剂的至少主要部分是无定形的。 当施用于水性使用环境时，固体无定形分散体提供CETP抑制剂的浓度增强。
-
2.发明授权Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase 有权胆固醇酯转移蛋白抑制剂和HMG-CoA还原酶的药物组合物公开(公告)号：US08828438B2
公开(公告)日：2014-09-09
申请号：US11920473
申请日：2006-05-22
Applicant: Dwayne Thomas Friesen , Bruno Caspar Hancock , Rodney James Ketner , David Keith Lyon , James Alan Shriver Nightingale , Ravi Mysore Shanker
Inventor： Dwayne Thomas Friesen , Bruno Caspar Hancock , Rodney James Ketner , David Keith Lyon , James Alan Shriver Nightingale , Ravi Mysore Shanker
CPC classification number: A61K45/06 , A61K9/1611 , A61K9/1635 , A61K9/1652 , A61K31/40 , A61K31/4706 , A61K2300/00
Abstract: A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase inhibitor), and a concentration enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concentration-enhancement of the CETP inhibitor when administered to an aqueous use environment.
Abstract translation: 固体无定形分散体包含胆固醇酯转移蛋白（CETP）抑制剂，3-羟基-3-甲基戊二酰辅酶A还原酶（HMG-CoA还原酶抑制剂）的抑制剂和浓度增强聚合物。 分散体中CETP抑制剂的至少主要部分是无定形的。 当施用于水性使用环境时，固体无定形分散体提供CETP抑制剂的浓度增强。
-
Search Results
2
records
(took 0.011 seconds)
